©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Potent Peptide Analogues of a G Protein Receptor-binding Region Obtained with a Combinatorial Library (*)

(Received for publication, October 27, 1995; and in revised form, November 10, 1995)

Edith L. Martin (1)(§) Stephanie Rens-Domiano (2)(§) Peter J. Schatz (1) Heidi E. Hamm (2)(¶)

From the  (1)Affymax Research Institute, Palo Alto, California 94304 and (2)Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, Illinois 60612

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The C terminus of the G protein alpha subunit represents an important site of interaction between heterotrimeric G proteins and their cognate receptors. We have screened a combinatorial peptide library based on the C terminus of the alpha subunit of G(t)(340-350) and have identified unique sequences that bind rhodopsin with high affinity. Six of these sequences, as both fusion proteins and synthetic peptides, were significantly more potent than the parent sequence in binding to and stabilization of metarhodopsin II. These sequences provide information about which residues are required for appropriate receptor interaction. We observed that in all the high affinity sequences, a positively charged residue at position 341 was changed to a neutral one. Thus, it appears that the receptor-G protein interaction was designed to be low affinity to ensure efficient catalysis of G protein activation. We also observed Cys-347 and Gly-348 to be invariant, and hydrophobic residues were always located at positions 340, 344, 349, and 350, demonstrating the critical nature of these residues. A composite of the structures of the high affinity sequences was modeled based upon the structure of rhodopsin-bound trNOESY NMR of this region of G ( Dratz, E. D., Fursteneau, J. E., Lambert, C. G., Thireault, D. L., Rarick, H., Schepers, T., Pakhlevaniants, S., and Hamm, H. E.(1993) Nature 363, 276-280) and provides insight into the complementary G protein-binding surface of the receptor.


INTRODUCTION

Understanding the structural basis of receptor-G protein (^1)interaction is essential to defining a molecular mechanism of signal transduction. Activated receptors display a high affinity binding site for heterotrimeric G proteins, which, depending on the receptor type, appears to consist of one or more of the cytoplasmic regions of the receptor. Interestingly, however, comparison of the primary sequences of receptors that are known to interact with the same G protein has not revealed the underlying consensus sequence. High affinity interaction of heterotrimeric G proteins with activated receptors requires the presence of both the G protein alpha and beta/ subunits. Three regions on the alpha subunit are known to be important for receptor interaction, the N-terminal 23 residues, an internal sequence that includes the TCAT region which contacts the guanine ring, and the C terminus(1) . The extreme C terminus of G protein alpha subunits is one of the critical points of contact with activated receptors(1, 2, 3, 4, 5, 6, 7) . This C-terminal region of G protein alpha subunits is also important in determining the specificity of receptor-G protein interaction(9) , although other regions of alpha subunits are also involved(10) . Synthetic peptides corresponding to the last 11 amino acids of alpha subunits have been shown to mimic the conformational effect of heterotrimeric G proteins on receptors by stabilizing the active, agonist-bound form of the receptor, although with low potency(1, 7, 8) . Additionally, C-terminal peptides from G subunits also can competitively block receptor-G protein interactions(1, 8) .

The advent of random peptide libraries displayed on bacteriophage (11, 12, 13) or bacterial plasmids (14) has brought the screening power of very large combinatorial libraries to the search for potent peptide agonists and antagonists, as well as to provide detailed structural analysis of the requirements for peptide-receptor interactions. In this study, we have used a random ``peptides-on-plasmids'' library approach (14) to identify potent rhodopsin-binding peptide sequences related to a C-terminal G peptide, G-340-350 (1, 7) from a library of greater than 10^9 peptides. Using this method, we have developed several high affinity analogues of G-340-350 and have gained insight into the structural requirements for peptide binding and stabilization of the activated conformation of rhodopsin, metarhodopsin II (Meta II).


MATERIALS AND METHODS

Bacterial Strains and Plasmids

Bacterial strains, plasmids, and library construction are essentially as described(15) . Escherichia coli ARI 814 (Delta(srl-recA) endA1 nupG lon-11 sulA1 hsdR17 Delta(ompT-fepC) DeltaclpA319::kan DeltalacI lacZU118) was used for all experiments. Plasmid pJS142 was used for library construction. A second plasmid, pELM3, a pMal-c2 derivative with a modified polylinker (New England Biolabs), was used for expression of maltose-binding protein (MBP) fusion proteins. This isopropyl beta-thiogalactopyranoside-inducible vector contains the E. coli malE gene with a deleted leader sequence, leading to cytoplasmic expression of the fusion proteins.

Library Construction

An oligonucleotide, ON-2333, was synthesized to encode a mutagenesis library based on the K341R derivative of the native 340-350 C-terminal sequence of G, IKENLKDCGLF (5`-GA GGT GGT NNK NNK NNK NNK att cgt gaa aac tta aaa gat tgt ggt ctg ttc TAA CTA AGT AAA GC). Uppercase letters denote positions synthesized with pure phosphoramidites or with equimolar mixes (N = A, C, G, and T; K = G and T). Lowercase letters denote bases synthesized with 70% of the indicated base and 10% of each of the other bases. This mutagenesis rate leads to approximately a 50% chance that a codon will be mutated to encode another amino acid. Additionally, four random NNK codons were synthesized on the 5`-end of the sequence to make a total of 15 randomized codons.

Panning

Buffers and general methods are described elsewhere (15) . In the dark, EDTA-washed rod outer segment (ROS) membrane fragments (16) were directly immobilized on Immulon 4 (Dynatech) microtiter wells (1 µg of protein/well) in cold 35 mM Hepes, pH 7.5, buffer containing 0.1 mM EDTA, 50 mM KCl, 1 mM dithiothreitol (HEK/DTT). After shaking for 1 h at 4 °C, unbound ROS were washed away with cold HEK/DTT. The wells were blocked with 1% BSA in HEK/DTT for 1 h at 4 °C. During this incubation the E. coli cells containing the library were lysed in a final volume of 10 ml. After centrifugation, cleared crude lysate was concentrated in a Centriprep 100 concentrator (Amicon). The blocked ROS-coated plate was rinsed briefly in HEK/DTT and exposed to room light for less than 5 min on ice to activate the rhodopsin. Immediately thereafter, the lysate was added to 48 wells for round 1 and incubated for 1 h at 4 °C. In the subsequent round, 24 ROS-coated wells were used for panning. Due to the reduction in library diversity only 4 wells were used in rounds 3 and 4. Equal numbers of wells without ROS were also included as a negative control in those panning rounds. Elution and amplification of the selected plasmids were performed as described(15) . Prior to elution in the third and fourth rounds, 1 mM G-340-350 analog, IRENLKDSGLF, was allowed to compete for 15 min at 4 °C to select for higher affinity peptides. In the fourth round of panning, the recovery of plasmids from ROS membrane-coated wells was 430-fold more than that from the same number of control wells.

ELISA

The entire population of peptide-coding sequences from round 4 was transferred from pJS142 into pELM3, and the fusion proteins were expressed for screening in a MBP ELISA(15) . All fusion proteins were assayed with and without immobilized EDTA-washed ROS membranes prepared as described(16) . In the dark, 1 µg/well ROS membranes were directly immobilized on Immulon 4 (Dynatech) microtiter wells in cold HEK/DTT. After 1-h incubation at 4 °C, unbound ROS were washed away with cold HEK/DTT. The wells were blocked with 1% BSA in HEK/DTT for 1 h at 4 °C, after which MBP fusion proteins were added for 30 min. Bound MBP fusion proteins were detected by rabbit anti-MBP antibodies. Alkaline phosphatase-conjugated goat anti-rabbit antibody was used to detect the primary antibody, and the assay was developed with p-nitrophenyl phosphate. The positive control for the assay was pELM17, which encodes the MBP fusion protein of G-340-350 peptide analog (K341R). pELM6, which expresses a MBP protein fused to a linker only, was used as the negative control. ``No lysate'' control wells were included to reflect any intrinsic nonspecific binding within the assay.

Some of the MBP fusion proteins were further purified on an amylose column (New England Biolabs) and eluted with 10 mM maltose as described by the supplier. The dose response for the ability of each of these MBP fusion proteins to compete with the LacI-G-K341R-340-350 fusion protein for binding to light-activated rhodopsin was measured in an ELISA format(15) . Microtiter wells were coated with 0.5 µg of ROS/well and blocked with BSA in the dark. Serial dilutions of purified MBP fusion proteins were made in HEK/DTT/BSA buffer. After light activation of the rhodopsin, each dilution was added to duplicate wells and then incubated for 45 min at 4 °C. The LacI fusion protein containing G-K341R-340-350 was then added. The incubation was continued for 30 min to allow the competition of the two protein fusions to take place, and the amount of bound LacI was detected by an anti-LacI antibody(15) . Dose-response curves were generated, and IC values were calculated using the computer programs Ligand and Deltagraph Pro 3.5.

``Extra'' Meta II Assay

Stabilization of Meta II was measured in an SLM Aminco DW2000 spectrophotometer essentially as described(7) , except that the EDTA-washed rhodopsin (5 µM) was incubated in a 50 mM Hepes buffer, pH 8.2, containing 100 mM NaCl, 1 mM MgCl(2), and 1 mM DTT. The samples were maintained at 5.3 °C by a water-cooled thermal jacketed cuvette holder. The resulting dose-response curves and EC values were derived by the non-linear regression program PRISM.

Peptide Synthesis

G-340-350 analogues were synthesized by the solid-phase Merrifield method using Fmoc(N-(9-fluorenyl)methoxycarbonyl) chemistry on an Applied Biosystems automated peptide synthesizer. Peptides were purified by reverse-phase HPLC using a C4 preparative column and an acetonitrile, 6 mM HCl gradient. The purified peptides were subjected to fast atom bombardment mass spectrometry and analytical reverse-phase HPLC to determine purity and authenticity. Peptides 18S, 18L, 23S, and 23L were synthesized by SynPep Corporation and were purified and characterized using similar methods.


RESULTS AND DISCUSSION

Library Construction and Panning

To explore the sequence requirements for binding of the C terminus of G to activated rhodopsin and to search for potent peptide analogues, we constructed a mutagenesis library based on a 15-amino acid sequence consisting of a 4-amino acid linker and 11 amino acids from the C-terminal analog, G-K341R-340-350(7) . To construct the library, we used the ``peptides-on-plasmids'' vector pJS142(14, 15) , which resulted in a library containing approximately 2 times 10^9 independent recombinants. The library peptides were fused to the C terminus of the DNA binding protein LacI. Each plasmid vector from which the fusion proteins are expressed contains two lacO DNA sequences to which the LacI fusion protein binds with high affinity, leading to the formation of peptide-LacI-plasmid complexes in each transformed cell in the library population. After cell lysis, the library complexes expressing peptides of interest were affinity purified by ``panning'' on immobilized rhodopsin. Plasmids recovered after each round of panning were amplified for additional rounds of panning after transformation of E. coli(14, 15) . To select for the highest affinity peptides in the population, we carried out the last two of the four total rounds of panning in the presence of a G-340-350 peptide analog as a competitor in a wash step to ``chase'' low affinity complexes off of the immobilized receptor. After the final round, the enriched population of peptide coding sequences was transferred to the vector pELM3 so that they were fused in frame with the E. coli MBP. Peptides fused to MBP can be analyzed in a competition ELISA where the resulting signal is a rough correlate of their affinity for the rhodopsin(15, 17) . Of 28 individually selected clones, 24 yielded a positive signal in the MBP ELISA (Fig. 1A). The signal intensities from these positive clones are stronger than that of the positive control clone, pELM17, which encodes the G-K341R-340-350 undecamer. DNA sequencing of these MBP ELISA-positive clones yielded 18 unique, readable sequences. The positive sequences are shown (Fig. 2B), as well as the C-terminal 11 amino acids of the known mammalian G protein alpha-subunits (Fig. 2A) for comparison. Also shown are the rhodopsin-specific binding sequences from the second round of panning, which were presumably lower affinity, on average, than those present after later rounds of panning. The resulting percent identity and similarity (homology) with G for each residue is in Fig. 2C. Interestingly, the four upstream amino acid linkers do not share an obvious consensus sequence.


Figure 1: A, ELISA of selected MBP fusion proteins binding to activated rhodopsin. In the dark, 1 µg/well ROS membranes were directly immobilized on Immulon 4 microtiter wells in cold HEK/DTT. The bound ROS was activated and exposed by light for less than 5 min on ice, and the fusion proteins were added for 30 min. Subsequent primary and secondary antibody incubations were performed as described for Table 1. The positive control for the assay was pELM17, which encodes the MBP fusion protein of G-340-350 peptide analog (K341R). pELM6, which expresses a MBP protein fused to a linker only, was used as the negative control. ``No lysate'' control wells were included to reflect any intrinsic nonspecific binding within the assay. B, competition of MBP fusion protein binding to activated rhodopsin by G(t). 1 µg/well ROS was directly immobilized in microtiter wells and 1 µM G(t) was allowed to bind to rhodopsin for 30 min at 4 °C before purified MBP fusion proteins were added in equal volume and incubated for an additional 30 min. The samples were then analyzed by ELISA as described in A.




Figure 2: A, comparison of the sequences of the C-terminal 11 amino acids of the known G protein alpha subunits. Darkly shaded amino acids are those conserved throughout G protein alpha-subunits, and lightly shaded residues are those which are similar (homologous). B, comparison of the sequences of the peptides identified from the fourth and second rounds of panning of the combinatorial library. Darkly shaded amino acids are those that remain identical to native G, and lightly shaded ones are those that have undergone replacement with similar amino acids. The fourth round was screened using an MBP ELISA and the second round screened using a LacI ELISA. C, percent identity and similarity (homology) of the library-derived sequences from the second and fourth rounds of panning. Based on the method for generating the oligonucleotides, 50% of the time the naturally occurring amino acid will be encoded.





Sequences derived from the fourth round of panning suggest that 2 of the 11 residues, Cys-347 and Gly-348, are absolutely required for binding to rhodopsin (Fig. 2). These two amino acids are conserved among all of the members of the G(t), G(i), and G(o) G protein subfamilies (Fig. 2A), and Cys-347 is the site of pertussis toxin modification in this subfamily(5) . These 2 residues are also part of a type II` beta turn, which is required for Meta II stabilization(7) . Other residues conserved within the G/G subfamily could be replaced only with amino acids having similar properties. Ile-340 is strictly conserved in this subfamily, and throughout G proteins it is generally only replaced with Leu (Fig. 2). Even among the most potent of the peptides (see below) Val, Leu, and Met substitution occurred, suggesting that several hydrophobic residues are acceptable. The large hydrophobic residues Phe or Tyr are found at the final position of G(i)/G(t) alpha subunits. Phenylalanine occurred almost exclusively in our study. The one exception, found in two of the sequences, was the much smaller hydrophobic residue, Leu. This did not appear to be detrimental, since it appeared in one of the more potent peptides, 9.

Several other amino acids in the C-terminal 11 residues are generally conserved throughout known G protein alpha subunits, although G and G are more heterogeneous than the others (Fig. 2A). Two Leu residues, Leu-344 and Leu-349, are absolutely conserved in all G proteins, yet in our peptides conservative substitutions were possible. Among the high affinity peptides, Leu-344 was always present, but Leu-349 was switched to Met in sequences 8 and 24. The conservation of hydrophobic residues at certain positions (340, 344, 349, and 350) suggests a hydrophobic component to the conserved binding pocket on the receptor. This, in fact, has been suggested by mutagenesis studies on muscarinic (18, 19) and beta-adrenergic (20) receptors.

Rhodopsin Binding and Meta II Stabilization by the Fusion Proteins and Peptides

As a rough indicator of potency, we initially examined the ability of the MBP fusion proteins to be competed off of light-activated rhodopsin by a single high concentration of G-Ac-K341R-340-350. Presumably, those that were not well competed would be significantly more potent than the native peptide. Six of the least strongly competed MBP-peptide fusion proteins were then chosen for further study. The affinities of these fusion proteins for light-activated rhodopsin were estimated using a competition ELISA. The IC values of these six MBP-peptide fusions range from 3.8 to 42 nM, up to 3 orders of magnitude more potent than the 6 µM IC of MBP-G-K341R-340-350 (encoded by plasmid pELM17) (Table 1). G(t), a much stronger competitor than its C-terminal peptide, was tested for its ability to compete with the purified MBP fusion proteins for binding to rhodopsin in the MBP ELISA. G(t), at 0.5 µM, inhibited binding of all six of the MBP fusion proteins, decreasing the signal by an average of 50% (Fig. 1B), indicating that these peptide sequences share the binding site on rhodopsin with G(t).

C-terminal peptides of G subunits cannot only bind to their cognate receptors but can mimic the heterotrimeric G proteins' ability to affect receptor conformation and stabilize the active state(1, 7, 8) . The fusion protein, MBP-G-K341R-340-350, was able to stabilize Meta II with an EC of greater than 100 µM. At similar concentrations, the MBP protein alone (encoded by plasmid pELM6) had no effect. The high affinity fusion proteins derived from the combinatorial library were significantly more potent than MBP-G-K341R-340-350 in their ability to stabilize Meta II (Fig. 3A). Their EC values ranged from 0.49 to 5.4 µM (Table 1).


Figure 3: A, Meta II stabilization by MBP fusion proteins. Dose response of Meta II stabilization by representative high affinity MBP-peptide fusion proteins, G(t) and G-Ac-K341R-340-350. EDTA-washed rhodopsin (5 µM) was incubated in a 50 mM Hepes buffer, pH 8.2, containing 100 mM NaCl, 1 mM MgCl(2), and 1 mM DTT at 5.3 °C, and ``extra'' Meta II was measured as described under ``Materials and Methods.'' Maximal Meta II stabilization (100%) was considered to be the amount of Meta II stabilized by a saturating amount of G(t) (5 µM). The resulting dose-response curves are presented for G(t) (), G-K341R-340-350 (box), MBP-8 (bullet), MBP-23 (), and MBP-24 (circle). B, Meta II stabilization by peptides. Dose-response curves for Meta II stabilization by G(t) (), G-K341R-340-350 (box), and peptides 8S (bullet), 23S (), and 24S (circle) are presented.



To examine the sequences directly, in the absence of the 43-kDa MBP fusion partner, we chemically synthesized the six 11-mer peptides (denoted ``S'') and compared them with the G-K341R-340-350 11-mer peptide. Dose-response studies in the competition ELISA revealed that the 11-mer peptides displayed higher binding affinity than the parent peptide by 2- (24S) to 300-fold (23S) (Table 1). The synthetic peptides were then tested for their ability to stabilize Meta II. The newly identified peptides were all significantly more potent than G-K341R-340-350 in their ability to stabilize Meta II (Fig. 3B). Their EC values ranged from 0.76 (23S) to 152 (24S) µM, which is up to 290 times higher affinity than the parent sequence (Table 1). Additionally, these peptide sequences also appear to be potent antagonists of receptor activation of G proteins, since the peptides competitively inhibit the ability of light-activated rhodopsin to stimulate GTPS binding to G in a dose-dependent fashion. (^2)

It is interesting to note that the relative potency of the 24S peptide decreased substantially in the absence of the fusion protein. In general, the MBP fusion proteins all appear to be of higher affinity than the peptides in both the binding and Meta II assays. This is probably due to the constraining effect on the N terminus of the peptide, which would lead to a decrease in conformational freedom. This difference between the fusion proteins and peptides was not as great in the Meta II assay, probably due to the higher sensitivity of the ELISA assay. ``Extra'' Meta II is measured as a tiny absorbance change (Delta0.02 absorbance unit), and to detect such a small change the concentration of rhodopsin must be high (>0.05 µM), thus limiting the dynamic range of the assay.

To examine the effect of the added four random N-terminal amino acids, the full-length 15-mer peptides were also synthesized for clones 18 and 23 (peptides 18L and 23L) (Table 1). Although no obvious consensus sequences were present in the four random residues extended upstream from the core library, this region contributes to the increase in affinity in these two peptides. Peptide 18L is approximately 70- and 16-fold more potent than the corresponding 18S 11-mer peptide in the binding and Meta II assays, respectively, whereas this difference is only 3-fold for peptides 23L and 23S.

By surveying a large number of peptide sequence possibilities unattainable by standard peptide synthetic techniques, we found several sequences that bind to rhodopsin with substantially higher affinity than the native sequence. Presumably, these analogues bind more tightly and dissociate at a slower rate. It is interesting that the screening procedure selected against a positive charge at position 341 but not at position 345 (Fig. 2B). In approximately 70% of the high affinity peptides from panning round 4 and all of the highest affinity peptides we fully characterized, the Lys-341/Arg-341 was changed to a non-charged group. This positive to neutral change correlates well with higher affinity. Such a change could have implications for the evolved functional properties of signaling pathways. In order to permit rapid and amplified information transfer, the receptor-G protein interaction must allow for rapid dissociation of the activated G protein. We described an activation-dependent conformational change of G-Ac-K341R-340-350 in its rhodopsin-bound conformation by trNOESY and speculated that this conformational change is important for the highly amplified G(t) activation process(7) . Especially marked changes occur in a helix-like tight turn at the N terminus involving Ile-340, Arg-341, Glu-342, and Asn-343, with formation of a salt bridge between Arg-341 and the free carboxyl of the C terminus in the inactive receptor-bound form and relaxation of this interaction in the activated form(7) . The hypothesis that the presence of a positive charge at position 341 might decrease the affinity of binding to receptor and increase the receptor's catalytic rate is directly testable using site-directed mutagenesis. Interestingly, a mutation that removes this positive charge (Arg-385 to His) has been reported to functionally uncouple G(s) from its receptor in a patient with Albright hereditary osteodystrophy(21) . It would be of interest to examine whether this mutation leads to a higher affinity for receptor. Other G proteins do not have a positive charge at this position (Fig. 2A), and we predict that these G proteins may have higher receptor affinity and lower activation rates.

The crystal structure of G has provided much information on its overall three-dimensional conformation(22, 23, 24, 25) . However, in the crystal structure of GbulletGDP (which in combination with the beta subunit is the rhodopsin binding conformation) the C-terminal region was disordered and not visible (23) . Only in the GTPS-bound form of G could any structural features of the C terminus be discerned(22) . Three possibilities are that 1) it is disordered and extended in the GDP-bound conformation in order to ``sense'' the activated receptor and conform to it by induced fit, 2) the disorder is an artifact of the crystal packing, or 3) it is disordered because it is missing an organizing site contributed by the N terminus, which was deleted from the G used for crystal formation.

In the absence of good crystallographic data on the C terminus, our data can be used to suggest an approximation of the tolerances of rhodopsin's binding site for the G-340-350 region by utilizing a combination of information on the peptide side chains that can be accommodated in each position and the structural information obtained by trNOESY(7) . We have constructed surface models of the original peptide and a composite peptide containing the bulkiest side chain at each position from the six highest affinity peptides using trNOESY data from (7) . The resulting models show that both the native and modified peptides have two distinctly different ``faces,'' one polar and the other hydrophobic. Overall, there are only slight changes in the shape of the hydrophobic side of the two peptides. The polar face of the modified peptide does, however, appear to be less densely packed than the native peptide and more negatively charged because of the loss of the positive charge at position 341 (Fig. 4). The surfaces of these peptides should be complementary to their binding site on rhodopsin's cytoplasmic surface. The actual residues that contact rhodopsin are not known, and their identification would greatly facilitate our understanding of the critical point-to-point interactions required for receptor-G protein interaction.


Figure 4: Solvent-accessible surfaces of original and high affinity peptides. The alpha-carbon / angles of the original peptide bound to inactive rhodopsin (determined by trNOESY (7) ) were used in the composite peptide, substituting the bulkiest side chains at positions that tolerate substitution (I340M, R341L, D346E, and L349M). The peptides have distinctive polar and hydrophobic surfaces. A and B show the polar surfaces of G-Ac-K341R-340-350 and the substituted peptide, respectively. The models were constructed using INSIGHT and GRASP (developed by A. Nicholls and B. Honig, Columbia University). The amino acids are labeled based on their sequence position(1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11) and the orientation similar to that previously shown(2) . We have not accounted for the possibility that the lack of a positively charged side chain at position 341, which interacts with the free C terminus, may cause global changes in the backbone structure.



This paper has demonstrated the power of using a combinatorial library to develop potent peptide analogues useful in furthering our understanding of rhodopsin-G(t) interactions, as well as having broader implications in the study of signal transduction systems. Additionally, this work will lay the structural framework by which therapeutic agents can be developed to interfere with signal transduction mediated via G proteins.


FOOTNOTES

*
This research was supported by Grant 06062 (to H. E. H.) from the National Institutes of Health and by grants from the American Heart Association and Research to Prevent Blindness. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
These two authors contributed equally to this work.

To whom correspondence should be addressed: Dept. of Physiology and Biophysics, University of Illinois at Chicago, 835 S. Wolcott, M/C 901, Chicago, IL 60612. Tel.: 312-996-7151; Fax: 312-996-7187; h-hamm@uic.edu.

(^1)
The abbreviations used are: G protein, GTP-binding protein; Meta II, metarhodopsin II; MBP, maltose-binding protein; ROS, rod outer segment(s); DTT, dithiothreitol; BSA, bovine serum albumin; GTPS, guanosine 5`-(-thio)-triphosphate; HPLC, high performance liquid chromatography; ELISA, enzyme-linked immunosorbent assay; trNOESY, transferred nuclear Overhauser effect NMR spectroscopy.

(^2)
C. E. Ford and H. E. Hamm, unpublished observation.


ACKNOWLEDGEMENTS

We would like to thank Lida Aris for assistance in the Meta II assays, Alex Spiess for peptide synthesis, Navreena Gill for assistance in computer modeling, Tracey Norris for oligonucleotide synthesis, and Glenn Dawes, Tom Cutler, and Ron Raab for DNA sequencing.


REFERENCES

  1. Hamm, H. E., Deretic, D., Arendt, A., Hargrave, P. A., Koenig, B., and Hoffman, K. P. (1988) Science 241, 832-835 [Medline] [Order article via Infotrieve]
  2. Sullivan, K. A., Miller, R. T., Masters, S. B., Beiderman, B., Heideman, W., and Bourne, H. R. (1987) Nature 330, 758-760 [CrossRef][Medline] [Order article via Infotrieve]
  3. Simonds, W. F., Goldsmith, P. K., Codina, J., Unson, C. G., and Spiegel, A. M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 7809-7813 [Abstract]
  4. Cerione, R. A., Kroll, S., Rajaram, R., Unson, C., Goldsmith, P., and Spiegel, A. M. (1988) J. Biol. Chem. 263, 9345-9352 [Abstract/Free Full Text]
  5. West, R. E., Moss, J., Vaughan, M., Liu, T., and Liu, T. Y. (1985) J. Biol. Chem. 260, 14428-14430 [Abstract/Free Full Text]
  6. Shenker, A., Goldsmith, P., Unson, C. G., and Spiegel, A. M. (1991) J. Biol. Chem. 266, 9309-9313 [Abstract/Free Full Text]
  7. Dratz, E. D., Fursteneau, J. E., Lambert, C. G., Thireault, D. L., Rarick, H., Schepers, T., Pakhlevaniants, S., and Hamm, H. E. (1993) Nature 363, 276-280 [CrossRef][Medline] [Order article via Infotrieve]
  8. Rasenick, M. M., Watanabe, M., Lazarevic, M. B., Hatta, S., and Hamm, H. E. (1994) J. Biol. Chem. 269, 21519-21528 [Abstract/Free Full Text]
  9. Conklin, R. B., Farfel, Z., Lustig, K. D., Julius, D., and Bourne, H. R. (1993) Nature 363, 274-276 [CrossRef][Medline] [Order article via Infotrieve]
  10. Lee, C. H., Katz, A., and Simon, M. I. (1995) Mol. Pharmacol. 47, 218-223 [Abstract]
  11. Cwirla, S. E., Peters, E. A., Barrett, R. W., and Dower, W. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6378-6382 [Abstract]
  12. Devlin, J. J., Panganiban, L. C., and Devlin, P. E. (1990) Science 249, 404-406 [Medline] [Order article via Infotrieve]
  13. Scott, J. K., and Smith, G. P. (1990) Science 249, 386-390 [Medline] [Order article via Infotrieve]
  14. Cull, M. G., Miller, J. F., and Schatz, P. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1865-1869
  15. Schatz, P. J., Cull, M. G., Martin, E. L., and Gates, C. M. (1996) Methods Enzymol. , in press
  16. Mazzoni, M. R., Malinski, J. A., and Hamm, H. E. (1991) J. Biol. Chem. 266, 14072-14081 [Abstract/Free Full Text]
  17. Gates, C. M., Stemmer, W. P. C., Kaptein, R., and Schatz, P. J. (1996) J. Mol. Biol. 255, in press
  18. Bluml, K., Mutschler, E., and Wess, J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7980-7984 [Abstract]
  19. Moro, O., Lameh, J., Hogger, P., and Sadee, W. (1995) J. Biol. Chem. 268, 22273-22276 [Abstract/Free Full Text]
  20. Cheung, A. H., Huang, R. R., and Strader, C. D. (1992) Mol. Pharmacol. 41, 1061-1065 [Abstract]
  21. Schwindinger, W. F., Miric, A., Zimmerman, D., and Levine, M. A. (1994) J. Biol. Chem. 269, 25387-25391 [Abstract/Free Full Text]
  22. Noel, J., Hamm, H. E., and Sigler, P. A. (1993) Nature 366, 654-663 [CrossRef][Medline] [Order article via Infotrieve]
  23. Lambright, D. G., Noel, J. P., Hamm, H. E., and Sigler, P. B. (1994) Nature 369, 621-628 [CrossRef][Medline] [Order article via Infotrieve]
  24. Sondek, J., Lambright, D. G., Noel, J. P., Hamm, H. E., and Sigler, P. B. (1994) Nature 372, 276-279 [CrossRef][Medline] [Order article via Infotrieve]
  25. Coleman, D. E., Berghuis, A. M., Lee, E., Linder, M. E., Gilman, A. G., and Sprang, S. R. (1994) Science 265, 1405-1412 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.